Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

被引：1

作者：

Wang, Jianxiang ^{[1
]}

Fu, Weijun ^{[2
]}

Bang, Soo-Mee ^{[3
]}

Huang, Honghui ^{[4
]}

Kim, Kihyun ^{[5
]}

Li, Wei ^{[6
]}

An, Gang ^{[1
]}

Lee, Je-Jung ^{[7
]}

Cai, Zhen ^{[8
]}

Jin, Jie ^{[8
]}

Wang, Yafei ^{[9
]}

Chim, C. S. ^{[10
]}

Rodriguez-Otero, Paula ^{[11
]}

Liberati, Anna Marina ^{[12
]}

Takamatsu, Hiroyuki ^{[13
]}

Lee, Jae Hoon ^{[14
]}

Dimopoulos, Meletios A. ^{[15
]}

Wroblewski, Susan ^{[16
]}

Carson, Robin ^{[16
]}

Qi, Ming ^{[16
]}

Wang, Jianping ^{[17
]}

Song, Yang ^{[18
]}

Jia, Bin ^{[19
]}

Yang, Xue ^{[19
]}

Liu, Wenyu ^{[18
]}

Li, Yunan ^{[20
]}

Zhang, Renyi ^{[21
]}

Hou, Jian ^{[4
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol Blood Dis Hosp, Tianjin, Peoples R China

[2] Shanghai Changzheng Hosp, Shanghai, Peoples R China

[3] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[4] Shanghai Jiao Tong Univ, Renji Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China

[5] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul, South Korea

[6] Jilin Univ, Dept Hematol, Ctr Oncol, Hosp 1, Changchun, Peoples R China

[7] Chonnam Natl Univ, Dept Hematol Oncol, Med Sch, Hwasun, Jeollanamdo, South Korea

[8] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China

[9] Tianjin Med Univ Canc Inst & Hosp, Dept Hematol, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China

[10] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China

[11] Univ Navarra Clin, Pamplona, Spain

[12] Azienda Osped Santa Maria, Terni, Italy

[13] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Hematol, Fac Med, Kanazawa, Japan

[14] Gachon Univ, Gil Med Ctr, Incheon, South Korea

[15] Natl & Kapodistrian Univ Athens, Athens, Greece

[16] Janssen Res Dev LLC, Spring House, PA USA

[17] Janssen Res Dev LLC, Raritan, NJ USA

[18] Janssen Res Dev LLC, Beijing, Peoples R China

[19] Janssen Res Dev LLC, Shanghai, Peoples R China

[20] Xian Janssen Pharmaceut Ltd, Med Affairs, Beijing, Peoples R China

[21] Xian Janssen Pharmaceut Ltd, Med Affairs, Shanghai, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-148937

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1648

引用

页数：5

共 50 条

[21] Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
Jakubowiak, Andrzej J.
Kumar, Shaji
Medhekar, Rohan
Pei, Huiling
Lefebvre, Patrick
Kaila, Shuchita
He, Jianming
Lafeuille, Marie-Helene
Cortoos, Annelore
Londhe, Anil
Mavros, Panagiotis
Lin, Thomas S.
Usmani, Saad Z.
[J]. ONCOLOGIST, 2022, 27 (07): : E589 - E596
[22] Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study (Sept, 10.1007/s00277-024-05958-8, 2024)
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Carson, Robin
Liu, Rui
Zhao, Man
Chen, Xi
Cui, Canchan
Hou, Jian
Wang, Jianxiang
[J]. ANNALS OF HEMATOLOGY, 2024,
[23] Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma
Daniele, Patrick
Mamolo, Carla
Cappelleri, Joseph C.
Bell, Timothy
Neuhof, Alexander
Tremblay, Gabriel
Musat, Mihaela
Forsythe, Anna
[J]. PLOS ONE, 2022, 17 (05):
[24] Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).
Cavo, Michele
Dimopoulos, Meletios A.
San-Miguel, Jesus
Jakubowiak, Andrzej J.
Suzuki, Kenshi
Yoon, Sung-Soo
Cook, Mark
Boccadoro, Mario
Ho, P. Joy
Pour, Ludek
Knop, Stefan
Doyen, Chantal
Masszi, Tamas
Blade, Joan
Wang, Jianping
Wroblewski, Susan
Deraedt, William
Qi, Ming
Mateos, Maria-Victoria
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25] Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE)
Cavo, M.
Dimopoulos, M. A.
San-Miguel, J.
Jakubowiak, A.
Suzuki, K.
Yoon, S-S
Cook, M.
Boccadoro, M.
Ho, P. J.
Pour, L.
Knop, S.
Doyen, C.
Crepaldi, A.
Masszi, T.
Blade, J.
Wang, J.
Wroblewski, S.
Deraedt, W.
Qi, M.
Mateos, M-, V
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 182 - 183
[26] One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone
Dimopoulos, Meletios A.
Mateos, Maria-Victoria
Cavo, Michele
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Kaplan, Polina
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Chiu, Christopher
Wang, Jianping
Kudva, Anupa
Kobos, Rachel
Wroblewski, Susan
Qi, Ming
San-Miguel, Jesus F.
Blade, Joan
[J]. BLOOD, 2018, 132
[27] Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
Gordan, Lucio Navarro
Tan, Carlyn Rose
Vescio, Robert
Ye, Jing Christine
Schinke, Carolina
Medhekar, Rohan
Fu, Alex Z.
Lafeuille, Marie-Helene
Thompso-Leduc, Philippe
Khare, Vipin
Reitan, John
Milkovich, Gary
Kaila, Shuchita
Davies, Faith
Usmani, Saad Z.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (01): : 55 - 63
[28] Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study
Gordan, Lucio
Tan, Carlyn Rose
Vescio, Robert
Ye, Jing Christine
Schinke, Carolina
Medhekar, Rohan
Fu, Alex
Lafeuille, Marie-Helene
Thompson-Leduc, Philippe
Khare, Vipin
Reitan, John
Milkovich, Gary
Kaila, Shuchita
Davies, Faith
Usmani, Saad
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S98 - S98
[29] Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study
Gordan, Lucio
Tan, Carlyn Rose
Vescio, Robert
Ye, Jing Christine
Schinke, Carolina
Medhekar, Rohan
Fu, Alex Z.
Lafeuille, Marie-Helene
Thompson-Leduc, Philippe
Khare, Vipin
Reitan, John
Milkovich, Gary
Kaila, Shuchita
Davies, Faith
Usmani, Saad Z.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S502 - S502
[30] Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone
Rodriguez-Otero, Paula
Boccadoro, Mario
Hajek, Roman
Fujisaki, Tomoaki
Lee, Jae Hoon
Martinez-Lopez, Joaquin
Lucio, Paulo
Nagy, Zsolt
Usenko, Ganna
Liberati, Anna Marina
Lazaroiu, Mihaela
Woszczyk, Dariusz
Takamatsu, Hiroyuki
Romejko-Jarosinska, Joanna
Knop, Stefan Tobias
Pavlovsky, Astrid
Forsyth, Cecily
Ishikawa, Takayuki
Gries, Katharine S.
Pei, Huiling
Kudva, Anupa
Ukropec, Jon
Wroblewski, Susan
Carson, Robin
Dimopoulos, Meletios A.
[J]. BLOOD, 2020, 136

← 1 2 3 4 5 →